Addex announces participation in the bio-europe 2023 conference

Geneva, switzerland, november 2, 2023 - addex therapeutics (six and nasdaq: adxn), a clinical-stage pharmaceutical company pioneering allosteric modulation-based drug discovery and development, today announced that tim dyer, chief executive officer, and dr. mikhail kalinichev, head of translational science, will be attending the bio-europe 2023 conference (november 6 – 8, 2023) in munich, germany.
ADXN Ratings Summary
ADXN Quant Ranking